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Dendritic cells of IgA nephropathy patients have an impaired
capacity to induce IgA production in naı¨ve B cells.
Background. IgA nephropathy (IgAN) is the most com-
mon primary glomerulonephritis worldwide, characterized by
mesangial IgA1 deposits. We have previously demonstrated that
IgAN patients have a hampered IgA immune respons after mu-
cosal challenge with a neoantigen. Dendritic cells are critically
involved in the initiation of humoral immune responses, not
only via activation of T-helper cells, but also via direct effect
on naı¨ve B cells. The aim of this study was to investigate the
capacity of dendritic cells from IgAN patients to regulate IgA
production.
Methods. Dendritic cells were generated by culturing mono-
cytes for 7 days in the presence of interleukin (IL)-4 and
granulocyte macrophage-colony-stimulating factor (GM-CSF).
Dendritic cells from either IgAN patients (N = 12) or controls
(N = 12) were cultured for 14 days with naı¨ve B cells in the
presence of CD40L-transfected mouse fibroblasts (L-CD40L
cells) and medium with or without IL-2 or IL-10. Supernatants
were tested for the presence of immunoglobulins by specific
enzyme-linked immunosorbent assay (ELISA).
Results. In the presence of CD40L and IL-10, dendritic cells
were able to increase immunoglobulin production by naı¨ve
B cells. Dendritic cells of IgAN patients induced significantly
(P = 0.026) less IgA production than dendritic cells of control
persons (2.30 lg/mL vs. 5.24 lg/mL), whereas no differences
were found in the IgG and IgM production. When dendritic cells
were replaced by supernatant of CD40L-stimulated dendritic
cells of patients and controls, IgA production was increased,
but no difference was seen between the two groups.
Conclusion. In the present study we show that dendritic cells
of IgAN patients have an impaired capacity to induce IgA pro-
duction in naı¨ve B cells, which might explain the observed IgA
hyporesponse upon mucosal challenge with a neoantigen.
IgA nephropathy (IgAN) is the most common primary
glomerulonephritis worldwide [1–3]. Overall, IgAN is the
cause of renal failure in ± 10% of the people being on
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chronic renal replacement therapy in Western Europe
and the United States. Patients usually present with mi-
croscopic hematuria and proteinuria. In renal biopsies,
IgAN is characterized by IgA1 and complement compo-
nent 3 (C3) deposits in the mesangium of the glomeruli
[4, 5]. After kidney transplantation, recurrent IgA de-
posits are found in the allograft in a high percentage of
the cases. Moreover, occasional accidental transplanta-
tion of a kidney of an IgAN patient leads to disappear-
ance of IgA deposits [6, 7]. Therefore, it is most likely that
the major cause of IgA deposition in the renal mesangium
lies in IgA itself or the interaction between IgA and the
mesangium.
The pathogenesis of IgAN is not clear. Several factors
have been implicated to play a role in the formation of
IgA immune deposits in the mesangium. Both quantita-
tive and qualitative differences in IgA seem to be a factor
involved in the pathogenesis [8, 9]. Detailed biochemical
analysis of IgA1 suggests that underglycosylated IgA1 is
enriched both in serum and in mesangial deposits [10,
11]. Moreover, it has been suggested that glycosylation
of IgA might be affected by the mode of B-cell activation
and the cytokine milieu [12].
A clinical observation is that upper respiratory tract
infections frequently lead to an increase of hematuria
(“synpharyngitic hematuria”) [13, 14]. Therefore, a dys-
regulation of the mucosal immune response of IgAN pa-
tients might play a role in the pathogenesis [1]. Mucosal
vaccination of IgAN patients with neoantigens was shown
to lead to an impaired mucosal and systemic IgA re-
sponse, compared with healthy persons [15, 16]. In these
studies, no differences in the antigen-specific IgG and
the IgM responses were measured. These results seemed
in conflict with the original idea that IgAN patients are
hyperresponders after vaccination, as suggested by the
higher serum IgA titers in most IgAN patients. The obser-
vation that systemic vaccination of IgAN patients with a
recall antigen appeared to give rise to a systemic and mu-
cosal hyperresponse might be explained by an increased
level of immunologic memory [17–19]. When we per-
formed a simultaneous mucosal and systemic vaccination
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with a neoantigen, only the mucosal challenge showed a
hyporesponse, whereas the systemic challenge was not
different between patients with IgAN and controls [15].
This suggests that the mucosal immune regulation has
specific regulatory features [20, 21].
Immunoglobulin production is the result of a com-
plex interaction between B cells, T cells, and antigen-
presenting cells like dendritic cells. Naı¨ve B cells are
IgM/IgD-positive and have to undergo a program of
affinity maturation, isotype switch, and plasma cell
differentiation before high affinity IgG or IgA antibod-
ies can be produced [22]. This process is tightly regu-
lated by activated T-helper cells through expression of
CD40L/CD154 and the production of cytokines. In the
hyper-IgM syndrome a genetic alteration of CD40L re-
sults in a deficit of circulating IgG and IgA [23, 24]. For
IgA production, cytokines like interleukin (IL)-10 and
transforming growth factor-b (TGF-b) have been shown
to determine the isotype specificity [25]. More recently it
has been shown in an in vitro model that dendritic cells
were capable to further increase IgA production in the
presence of IL-10 and CD40L [26, 27]. Therefore, den-
dritic cells seem to have a direct effect on B cells, next to
its well-established role in the activation of T-helper cells
[28, 29].
In the present study, we investigated the capacity of
dendritic cells from IgAN patients to induce IgA pro-
duction in naı¨ve B cells in vitro and compared this with
dendritic cells from healthy volunteers. We found that
dendritic cells from IgAN patients induce less IgA pro-
duction, whereas no differences for IgG and IgM were
found.
METHODS
Selection of IgAN patients
Biopsy-proven IgAN patients were selected for en-
try in this study. Patients did not take immunosuppres-
sive drugs within a 3-month period before blood samples
were taken. Age- and gender-matched healthy controls
were selected. No infections or macroscopic hematuria
were present at the time of blood sampling.
Mean age of the patients was 42 years versus 39 years
of the controls (Table 1). The male:female ratio was
83%:17% in both groups. Renal function was preserved
and stable in most of the patients. Mean creatinine clear-
ance was 78 mL/min. Only one patient had a creatinine
clearance lower than 25 mL/min. Proteinuria was mild
with a mean value of 1.3 g/L. The study was approved by
the Ethical Committee of the Leiden University Medical
Center. All individuals gave informed consent.
Generation of dendritic cells
Fifty milliliters of heparinized peripheral blood was
collected from each IgAN patient and healthy control
Table 1. Characteristics of IgA nephropathy (IgAN) patients and
control persons
IgAN patients Controls
Number 12 12
Mean age years (range) 42 (22–62) 39 (30–52)
Male/female 10/2 10/2
Years since diagnosis (range) 8 (1–22)
Serum creatinine lmol/mL (range) 135 (79–347) ND
Creatinine clearance mL/min (range) 78 (19–117) ND
Proteinuria g/L (range) 1.3 (0–1.9) ND
Erythrocyturia (0 to 4+) 2+ ND
ND is not determined.
person. Peripheral blood mononuclear cells (PBMCs)
were isolated by Ficoll-Hypaque (Sigma Chemical Co.,
St. Louis, MO, USA) density gradient centrifugation.
Cells were washed three times, to remove Ficoll and
thrombocytes. Subsequently, monocytes were isolated by
Percoll (Pharmacia, Uppsala, Sweden) gradient centrifu-
gation and plastic adherence for 2 hours in 6-well cul-
ture plates (2.5 × 106 cells/well) (Costar, Cambridge,
MA, USA). Adherent monocytes were cultured for 7
days in RPMI 1640 containing 10% heat-inactivated
fetal calf serum (FCS) and penicillin/streptomycin (all
from Gibco/Life Technologies, Breda, The Netherlands),
in the presence of 5 ng/mL granulocyte monocyte-
colony-stimulating factor (GM-CSF) (Leucomax) (No-
vartis Pharma B.V., Arnhem, The Netherlands) and 10
ng/mL IL-4 (Peprotech, Rocky Hill, NJ, USA) [30].
Analysis of cell surface phenotype by flow cytometry
Cells were harvested and washed in phosphate-
buffered saline (PBS) containing 1% bovine serum
albumin (BSA) and 1% heat-inactivated normal human
serum and 0.02% NaN3. Fluorescence-activated cell
sorter (FACS) analysis was performed using monoclonal
antibody against CD1a (Leu-6) and CD14 (Leu-M3)
(both Becton Dickinson & Co., Mountain View, CA,
USA) and CD86 (IT2.2) (Pharmingen, San Diego, CA,
USA) and CD209 (mouse antihuman DC-SIGN, AZN-
DI, kindly provided by Professor Yvette van Kooyk. Free
University Medical Centre, Amsterdam, The Nether-
lands). Staining was visualized by using polyethylene-
conjugated goat-antimouse Ig (Dako, Glostrup,
Denmark), assessed for fluorescence using a FAC-
Scan and analyzed with WinMDI software (Becton
Dickinson & Co.).
Isolation of serum IgD+ (sIgD+) B lymphocytes
B cells were isolated from tonsils by the Ficoll-
Rosetting method [25]. Purified sIgD+ B lymphocytes
were separated using a preparative magnetic cell sorter
(MACS) (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany) according to the experimental procedure
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described in detail by Miltenyi et al [31]. IgD was ex-
pressed on >99% of the sIgD+ B cell population as as-
sessed by FACScan analysis (Becton Dickinson & Co.).
B-cell activation
All cultures were performed in Iscove’s modified Dul-
becco’s medium (IMDM) glutamax (Gibco/Life Tech-
nologies) supplemented with 10% heat-inactivated FCS
and ITS (insulin 5 lg/mL, transferrin 5 lg/mL, and se-
lenium 5 ng/mL final concentration) (Sigma Chemical
Co.).A total of 1 × 104 IgD+ B cells were cultured in
the presence of 1 × 104 irradiated (33 Gy) dendritic cells
and 0.25 × 104 irradiated (75 Gy) murine L cell fibrob-
lasts stably transfected with human CD40L (L-CD40L
cells) [32] in a final volume of 200 lL in 96-well round
bottom tissue culture plates (Costar) [26]. In each exper-
iment, cells were cultured in the presence of medium, IL-2
(20 U/mL) (Chiron, Emeryville, CA, USA), or IL-10 (50
ng/mL) (Schering Plough, Dardilly, France). Each culture
condition was performed in fivefold. Conditions without
dendritic cells and/or without B cells served as negative
controls. Supernatant was harvested after 14 days.
Generation of supernatant from dendritic cells
A total of 5 × 104 dendritic cells were cultured for 72
hours in combination with 1 × 104 irradiated L-CD40L
cells or 1 × 104 L-Orient cells in a total volume of 500
lL in IMDM glutamax supplemented with 10% heat-
inactivated FCS and ITS. Supernatant was harvested and
stored at −20◦C until further use.
B-cell experiments with supernatant of dendritic cells
All cultures were performed in IMDM glutamax sup-
plemented with 10% heat-inactivated FCS and ITS. A to-
tal of 1 × 104 IgD+ B cells were cultured in the presence
of 50 lL supernatant of CD40L-stimulated or unstim-
ulated dendritic cells and 0.25 × 104 irradiated (75 Gy)
L-CD40L cells with or without IL-10 (50 ng/mL) in a final
volume of 200 lL in 96-well round bottom tissue culture
plates (Costar). Each culture condition was performed in
fivefold. Conditions without supernatant and/or without
B cells served as negative controls. Culture supernatant
was harvested after 14 days and tested for Ig by enzyme-
linked immunosorbent assay (ELISA).
Immunoglobulin quantification
IgA, IgA1, IgA2, IgG, and IgM levels were determined
by specific sandwich enzyme-linked immunosorbent as-
say (ELISA), as described [15]. All ELISAs were per-
formed in 96-well polystyrene plates (Greiner) (Alphen
a/d Rijn, The Netherlands). Optical density was measured
at 415 nm on a microplate reader (Bio-Kinetics Reader
EL 312e) (Biotek Instruments Inc., Winooski, VT, USA).
IL-10 quantification
IL-10 was measured by a commercially available
ELISA kit (Sanquin) (Amsterdam, The Netherlands)
and was used as indicated by the manufacturer.
Statistical analysis
Statistical analysis was performed, using Student t test.
P values less than 0.05 were considered significant.
RESULTS
Immunoglobulin production is dependent on the pres-
ence of CD40L and increased by dendritic cells
To be able to investigate the capacity of dendritic cells
of IgAN patients to modulate IgA production by naı¨ve
IgD+ B cells, we established a culture system based on
the presence of L-CD40L cells, IgD+ naı¨ve B cells, and
recombinant cytokines. Independent of which cytokines
were used, only very low concentrations of immunoglob-
ulins were detected in the absence of CD40L. In the pres-
ence of CD40L, the immunoglobulin production of all
different isotypes was strongly up-regulated (Fig. 1). This
Ig production is dependent on the presence of IL-10 and
is not supported by IL-2. Next, monocyte-derived den-
dritic cells were added to CD40L-activated B-cell cul-
tures. In the absence of exogenous cytokines, dendritic
cells did not significantly stimulate Ig production. How-
ever, in the presence of IL-10 and also in the presence
of IL-2 [33] dendritic cells stimulated production of IgA,
IgG, and IgM (Fig. 2). This model allows the investiga-
tion of the B-cell stimulating capacity of dendritic cells of
patients with IgAN.
No phenotypic differences between dendritic cells of
IgAN patients and control persons
Immature dendritic cells were generated by culturing
monocytes from patients and controls in the presence of
IL-4 and GM-CSF during 7 days. Monocytes are nega-
tive for CD1a and DC-SIGN and have high expression of
CD14. Immature dendritic cells have surface expression
of DC-SIGN, a specific dendritic cell marker, and have
high expression of CD1a and low expression of CD14
(Fig. 3A). The phenotype of immature dendritic cells of
IgAN patients and controls did not differ in expression of
DC-SIGN (Fig. 3B). Pilot experiments showed that indi-
vidual contaminating B cells in the dendritic cell popula-
tion could affect the outcome of Ig production. This effect
could be prevented by irradiation of (30 Gy) the den-
dritic cell population. Irradiation did not affect CD40L-
induced functions of dendritic cells, like IL-10 production
(Fig. 4A) or CD86 expression (Fig. 4B).
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Fig. 1. Immunoglobulin production is dependent on CD40L and inter-
leukin (IL)-10. Highly purified IgD+ B cells (104) were cultured with 75
Gy irradiated nontransfected L cells (L-orient) or CD40L transfected L
cells (L-CD40L) (0.25 × 104) in the presence of IL-2 (20 U/mL) or IL-
10 (50 ng/mL) as indicated. After 14 days supernatants were harvested
and tested for IgA, IgG, and IgM production using specific enzyme-
linked immunosorbent assays (ELISAs). Data shown are the mean ±
SD of quadruple cultures and represents one out of three independent
experiments.
Coculture of dendritic cells from IgAN patients with
naı¨ve B cells results in a reduced increase in IgA
production
In order to compare the capability of dendritic cells
from IgAN patients with dendritic cells from healthy vol-
unteers in the induction of IgA switch in naı¨ve B cells,
monocytes were isolated from IgAN patients (N = 12)
and healthy volunteers (N = 12). Controls and IgAN pa-
tients were always tested in parallel with the same source
of B cells and the same L-CD40L cells. Coculture in the
presence of IL-10 resulted in less IgA production induced
by dendritic cells from IgAN patients as compared to
dendritic cells from healthy control persons (5.34 lg/mL
versus 2.34 lg/mL) (P = 0.026) (Fig. 5A). No difference
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Fig. 2. Dendritic cells (DCs) increase Ig production by naı¨ve B cells.
Highly purified IgD+ B cells (104) were cultured with 75 Gy irradiated
CD40L transfected L cells (0.25 × 104) in the absence of dendritic cells
or in the presence of dendritic cells (104), in the presence of interleukin
(IL)-2 (20 U/mL) or IL-10 (50 ng/mL) as indicated. After 14 days, super-
natants were harvested and tested for IgA, IgG, and IgM production
using specific enzyme-linked immunosorbent assays (ELISAs). Data
shown are the mean ± SD of fivefold cultures and are representative of
three independent experiments.
between patients and controls was observed when co-
cultures were performed in the presence of IL-2. To de-
termine the specificity for the IgA regulation, also IgG
and IgM were measured in the same supernatants. In all
conditions, there were no differences between the IgAN
patient group and the control persons with respect to IgG
and IgM production (Fig. 5B).
In our analysis, it was clear that there was a large in-
dividual variation. Therefore, next to the mean absolute
production of IgA, we calculated the production of IgA
induced by the patient-dendritic cells as a ratio of the
response induced by control-dendritic cells in the same
experiment. From this analysis, it is clear that, although
the mean ratio of the 12 patients investigated is 0.43 ±
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Fig. 3. Analysis of CD1a, CD14 and DC-SIGN expression on mono-
cytes and immature dendritic cells (DCs) from controls and patients
with IgA nephropathy (IgAN). (A) Surface expression of CD1a, CD14,
and DC-SIGN on monocytes (upper panel) and monocyte-derived den-
dritic cells (lower panel) was determined using fluorescence-activated
cell sorter (FACS) analysis. Specific staining is represented by the filled
histograms and control staining by the open histograms. Shown is a
representative example of dendritic cells from a control. (B) Surface
expression of DC-SIGN on dendritic cells from control persons and
dendritic cells from IgAN patients was determined using FACS anal-
ysis. Shown are the mean fluorescence intensity (MFI) ± SD of five
control persons and five IgAN patients.
0.32, this ranged between a complete deficiency (ratio
<0.05) and a normal response (ratio 1.05) (Fig. 6).
Dendritic cells from IgAN patients induce less IgA1 and
IgA2 production than dendritic cells from healthy control
persons
Next to the measurements of total IgA, also produc-
tion of IgA subclasses, IgA1 and IgA2 were determined.
Comparable with total IgA, the addition of dendritic cells
together with IL-2 and IL-10 to naı¨ve B cells induced both
IgA1 and IgA2 production. In line with previous results
and with the difference in serum concentrations of these
subclasses, the production of IgA1 was much stronger. As
observed for total IgA, dendritic cells derived from IgAN
patients induced less IgA1 as well as IgA2 compared to
controls, which was again restricted to the conditions with
exogenous IL-10 (Fig. 7).
Supernatant from cultured dendritic cells can induce IgA
production in the presence of IL-10
In order to investigate whether a soluble factor, pro-
duced by dendritic cells, is responsible for the differences
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Fig. 4. Irradiation of dendritic cells does not influence CD40L-induced
interleukin (IL)-10 production and CD86 expression. (A) Dendritic
cells (5 × 104) were either irradiated (33 Gy) or not irradiated and
cultured for 72 hours in the presence of control L cells or CD40L-
transfected L cells (104). IL-10 production was measured by specific
enzyme-linked immunosorbent assay (ELISA). Shown are the mean
± SD of quadruple cultures. (B) Surface expression on denritic cells
of CD86 was determined by fluorescence-activated cell sorter (FACS)
analysis. Shown is the mean of three experiments.
in IgA production between the two groups, we generated
supernatant from CD40L-stimulated dendritic cells and
from dendritic cells cultured without CD40L. After 72
hours, supernatant from this culture system was harvested
and added to naı¨ve B cells in the presence of CD40L with
or without IL-10. In the absence of exogenous IL-10, den-
dritic cell supernatant could not induce IgA production
(data not shown). However in the presence of IL-10, es-
pecially supernatant of CD40L-activated dendritic cell
could augment IgA production. However, it should be
noted that this effect is small compared to the effect of
intact cells and importantly did not show a difference be-
tween controls and patients with IgAN (Fig. 8A). In the
same experiments, irradiated dendritic cells were also in-
vestigated using the same B cells demonstrating again a
hyporesponse of dendritic cells from IgAN patients (Fig.
8B).
DISCUSSION
In the present study, using an in vitro model, we show
that monocyte-derived dendritic cells of IgAN patients
have a reduced capacity to induce IgA1 and IgA2 pro-
duction in naı¨ve B cells compared to dendritic cells from
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Fig. 5. Dendritic cells from IgA nephropathy (IgAN) patients induce less net IgA production compared with controls. (A) Highly purified IgD+ B
cells (104) were cultured with 75 Gy irradiated CD40L-transfected L cells (0.25 × 104) in the presence of dendritic cells from controls (N = 12) or
in the presence of dendritic cells (104) from patients with IgAN (N = 12), in the presence of interleukin (IL)-2 (20 U/mL) or IL-10 (50 ng/mL) as
indicated. After 14 days, supernatants were harvested and tested for IgA. Data shown are the mean ± SEM of fivefold cultures of three independent
experiments. (B) IgG and IgM production was measured using specific enzyme-linked immunosorbent assays (ELISAs). Data shown are the mean
± SD of fivefold cultures of three independent experiments.
control persons. This difference was seen provided that
CD40L and IL-10 were present. In contrast, IL-2 also
increased immunoglobulin production, but in this con-
dition there was no difference in the B-cell stimulatory
capacity of dendritic cells derived from IgAN patients
or controls. No differences in IgG and IgM production
were measured, independent of the different cytokines
that were used. Addition of supernatant from CD40L
stimulated dendritic cells to naı¨ve B cells resulted in Ig
production, but did not result in a difference between con-
trols and IgAN patients. This suggests that a dendritic cell
membrane-bound factor is responsible for the difference.
IgAN is a disease with a wide variety in clinical presen-
tation and outcome. Some patients have a rapidly pro-
gressive renal deterioration leading to renal failure within
a short time period, while others have stable kidney func-
tion for many years. Eventually about 30% to 40% of
the patients will develop renal failure. It is generally ac-
cepted that genetic factors are involved in the pathogen-
esis of IgAN [34]. Not only familial cases of IgAN have
been described, but also a linkage between locus 6q22-23
and IgAN has been described [35, 36]. It is tempting to
speculate that the variation in IgA stimulatory capacity
(Fig. 6) might relate to some of these genetic factors.
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Fig. 6. Ratio of IgA production induced by
dendritic cells (DCs) from patients relative to
controls. Mean individual IgA production in-
duced by dendritic cells from patients with
IgA nephropathy (IgAN) is divided by the
mean IgA production induced by dendritic
cells from control persons and expressed as
a ratio. Shown are the mean +SD of five mea-
surements.
Alternatively, the in vitro hyporesponsiveness could po-
tentially relate to the severity of IgAN. However, in our
study there was no correlation between clinical parame-
ters like creatinine clearance or hematuria and the IgA-
inducing capacity (data not shown).
Vaccination studies have clearly demonstrated that pa-
tients with IgAN have a disturbed regulation of the mu-
cosal immune response. Using cholera toxin subunit B
(CTB) as a neoantigen we have previously shown that
patients with IgAN show a specific IgA hyporesponsive-
ness, with normal IgG and IgM responses [15]. Impor-
tantly, simultaneous systemic administration of another
neoantigen did not result in an IgA hyporesponse. These
results indicate that the defects observed in IgA produc-
tion are not generalized, but might be confined to the
mucosal compartment. Regulation of IgA production is
a complex process dependent on B cells, T cells, and
antigen-presenting cells, but might also be affected by
environmental mucosal factors. Previous in vitro studies
investigating B cells or T cells of IgAN patients have not
clearly pinpointed toward a molecular defect [37–39].
Total IgA production depends on IgA switch by IgD+
B cells [26] and further proliferation and differentiation
of these B cells. Class switch to IgA is a complex event, in
which rearrangement of genes has to take place [40–42].
This process is dependent on the interaction between T
cells and B cells and is influenced by many other factors.
A key role in this process is the interaction between the
tumor necrosis factor receptor (TNF-R) member, CD40
and its ligand [43]. This is demonstrated in the hyper-IgM
syndrome in which a genetic alteration of the CD40L
gene is responsible for low amounts of serum IgA, IgG,
and IgE [23, 24]. Next to CD40L, IgA production is regu-
lated by cytokines like IL-10 and TGF-b that act directly
on B cells. Moreover, as also shown in this study, den-
dritic cells can further increase IgA production. Previous
studies using similar IgD+ tonsillar B cells have demon-
strated that dendritic cells augment the isotype switch
process as proven by the increase in switch circles [44].
Although our system did not allow a direct investigation
of the switch process, it is likely that this contributes to
the increased IgA production. The nature of the den-
dritic cells signal promoting IgA production is at present
not known. Although there is a B-cell stimulating factor
in the supernatant of activated dendritic cells, our ex-
periments with supernatant suggest that the difference
between patients and controls seems to be caused by a
membrane factor. Recently it has been shown that sig-
naling through B-cell activating factor (BAFF), another
member of the TNF superfamily, can also augment IgA
switch in a CD40-independent manner. However, it was
shown that BAFF acted in concert with anti-IgM B-cell
activation, but not in concert with CD40 signaling [45].
Moreover, in preliminary experiments, we were not able
to show BAFF expression on normal monocyte-derived
dendritic cells (data not shown). Therefore, it is not likely
that difference in BAFF expression can explain the ob-
served in vitro differences in IgA production.
In the present study we have investigated monocyte-
derived dendritic cells, and have tried to link the func-
tional capacity of these cells to the observed mucosal
hyporesponsiveness. At present it is unclear how these
cells relate to mucosal dendritic cell populations. It will
be a major technical challenge to investigate the func-
tional capacities of mucosal dendritic cells directly, espe-
cially due to the limited access to mucosal tissues of these
patients. However, an intruiging observation in our study
was that the defective IgA production, induced by den-
dritic cells, was only observed in the presence of IL-10.
When dendritic cells were combined with IL-2, there were
no functional differences between patients and controls.
This suggests that there are at least two different mecha-
nisms by which dendritic cells can increase IgA produc-
tion by naive B cells. Until now there are no clues about
the underlying molecular mechanisms. Similarly, it is not
clear under which conditions in vivo IgA production is
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Fig. 7. Dendritic cells from patients with IgA nephropathy (IgAN)
induce less IgA1 and IgA2. Highly purified IgD+ B cells (104) were
cultured with 75 Gy irradiated CD40L-transfected L cells (0.25 × 104)
in the presence of dendritic cells from control persons (N = 12) or in
the presence of dendritic cells (104) from patients with IgAN (N = 12),
in the presence of interleukin (IL)-2 (20 U/mL) or IL-10 (50 ng/mL)
as indicated. After 14 days supernatants were harvested and tested for
IgA1 (A) and IgA2 (B). Data shown are the mean ± SD of fivefold
cultures of three independent experiments.
under the control of IL-2 or IL-10. Genetic inactivation
of IL-10 in mice does not result in major B cell defects or
reduced circulating Ig levels [46], whereas IL-2 deficiency
does show dramatic reduction of circulating Ig levels [47].
In both cases, the mice develop chronic mucosal inflam-
mation, suggesting a role in mucosal immune regulation
[46, 48]. However, it seems that expression of IL-10 is
more widely distributed and that IL-10 has a more im-
portant role as an anti-inflammatory mediator [49, 50].
It would be attractive to link the differential response in
combination with IL-2 or IL-10, with the observed selec-
tive deficiency of a mucosal challenge, as discussed above
[15]. Which local mucosal factors contributed to the ear-
lier described IgA hyporespons after vaccination remains
unclear. It certainly needs further research to determine
the precise role of dendritic cells and IL-10 in the regula-
tion of mucosal IgA production.
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Fig. 8. Supernatant of CD40L stimulated dendritic cells (DC) can in-
duce IgA switch, but to a lesser extent than dendritic cells. (A) Dendritic
cells (5 × 105) of control persons and IgA nephropathy (IgAN) patients
were cultured in the presence of medium, control L cells (unstimulated
supernatant) or CD40L-transfected L cells (stimulated supernatant)
(105) in a total volume of 500 lL. After 72 hours, supernatants were
harvested and 50 lL of each supernatant was added to naı¨ve B cells
(104) in the presence of interleukin (IL)-10 (50 ng/mL). After 14 days,
supernatant was harvested and tested for IgA, using specific enzyme-
linked immunosorbent assay (ELISA). (B) Dendritic cells (104) from
the same control persons and IgAN patients were added to naı¨ve B cells
(104) in the presence of medium or IL-10 (50 ng/mL). After 14 days,
supernatant was harvested and tested for IgA, using specific ELISA.
CONCLUSION
The current data strongly suggest that dendritic cells
of IgAN patients have an impaired capability to enhance
IgA production. These data support the results from an
earlier study in which mucosal vaccination was accom-
panied with an IgA hyporesponse [15]. The pathogenetic
role of IgA hyporesponsiveness in IgAN could be that
an initially inadequate clearance of an antigen leads to
a prolonged immune reaction. This prolonged immune
reaction could eventually lead to an increased serum IgA
titer. Which molecular factors are responsible for the im-
paired IgA response and whether the impaired capacity
to induce IgA switch is restricted to certain subsets of
dendritic cells is still unknown and further studies are
needed to resolve these questions.
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